Suppliers in Taylorsville, UT
6 Medicare Suppliers found. Showing 1 - 6
 Walgreens #6961 Durable Medical Equipment & Medical Supplies Location: 4668 S Redwood Rd, Taylorsville, Utah 84123 Phone: (801) 967-4972 |
Walmart Pharmacy 10-1686 Durable Medical Equipment & Medical Supplies Location: 5469 S Redwood Rd, Taylorsville, Utah 84123 Phone: (801) 264-9797 |
Harmons's Pharmacy #73 Community/Retail Pharmacy Location: 5454 S Redwood Rd, Taylorsville, Utah 84123 Phone: (801) 967-9185 |
Cns Respiratory Services Home Infusion Therapy Pharmacy Location: 3685 West 6200 South, Taylorsville, Utah 84129 Phone: (801) 973-0900 |
Cns Professional Services Durable Medical Equipment & Medical Supplies Location: 3685 W 6200 S, Taylorsville, Utah 84129 Phone: (801) 233-6120 |
Standard Opticla Company Medicare Supplier Location: 3754 W 5400 S, Taylorsville, Utah 84129 Phone: (801) 964-9911 |
News Archive
Link between BCG and lower COVID-19 mortality disproved by new analysis
The association between BCG (Bacillus Calmette-Guérin) vaccination and its purported beneficial effect on COVID-19 transmission/mortality rates was challenged in an expert appraisal of Diamond Princess cruise ship data. At the same time, cross-national differences previously reported were shown to be flawed, reports a new medRxiv study.
Playing football could help lower blood pressure in women aged 35-50
The World Cup in Brazil may be attracting a global armchair audience of millions, but new research has shown that playing football could help lower blood pressure in women aged 35-50.
Designer SARS-CoV-2 RBD vaccine produces dramatically improved antibody response in preclinical trials
The importance of computational modeling in the prediction of the course of the ongoing COVID-19 pandemic, as well as evaluating multiple potential drug leads, has never been more clear. Now, a new study describes a set of designer vaccine antigens that may improve vaccine stability as well as enhance the neutralizing antibody response.
Hepatic encephalopathy drug XIFAXAN 550 mg tablets receives FDA marketing approval
Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration has granted marketing approval for XIFAXAN 550 mg tablets for reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. HE is a serious disorder caused by chronic liver failure, resulting in cognitive, psychiatric and motor impairments. This approval was supported by findings from the largest randomized trial of maintenance therapy in HE conducted to date, which assessed the efficacy and safety of XIFAXAN 550 mg tablets and demonstrated a statistically significant and clinically meaningful reduction in the risk of overt HE recurrence.
Obese Americans report far greater overall satisfaction with weight loss surgery, medications
Obese and overweight Americans who have tried losing weight report far greater overall satisfaction with weight loss surgery and prescription weight loss medications than with diet, exercise and other self-modification methods, an Internet survey finds.
› Verified 1 days ago